About a third of people on cagrilintide (31.6%) achieved 15% weight loss or more, compared to roughly 1 in 20 (4.7%) on placebo
Category 2 Placement: The FDA placed BPC-157 in Category 2 of the 503A bulk drug substances list, citing "significant safety concerns." This effectively blocked compounding pharmacies from preparing BPC-157 formulations for patients
A review of feature selection methods for machine learning-based disease risk prediction
Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials
After having these shots, Asian women reported feeling more energised, having stronger immune systems, having more sex desire, and having brighter, whiter, more beautiful skin
The interesting part of this study is that there was no separation of patients by underlying cause of knee pain